Literature DB >> 11032402

IFN-gamma facilitates release of class II-loaded intracellular pools in trophoblast cells: a novel property independent of protein synthesis.

I Athanassakis1, A Ranella, S Vassiliadis.   

Abstract

Interferon-gamma (IFN-gamma) is an abortion-inducing factor, yet its effects in such a reaction are subject to various levels of regulation. The trophoblast cell line TROPHO-1 can be induced by IFN-gamma to express mRNA and surface class II major histocompatibility complex (MHC) proteins after 8 and 48 h of stimulation, respectively. Untreated cells, however, show an intracellular accumulation of class II antigens earlier (6 h), indicating the existence of MHC pools in the cystosol independent of any induction. On addition of IFN-y, immunofluorescence, subcellular fractionation, and ELISA experiments showed that class II antigen activity detected in the endosomal compartments of the cells could be measured in the culture supernatants. These soluble class II proteins, when isolated and purified using magnetic bead isolation techniques and tested in SDS-PAGE gel and Western blot experiments, had a molecular weight of 70 kDa. Administration of these molecules to pregnant mice as culture supernatants increased the abortion rate and decreased maternal hematocrit levels, effects that could be immunoabsorbed by anti-I-A(d) monoclonal antibodies (mAb). These results indicate that although surface class II molecules are not expressed on trophoblast cells, they accumulate in endosomal compartments and can be released from the cells on addition of IFN-gamma. This new IFN-gamma property, to mobilize intracellular pools of class II MHC antigens in trophoblast cells independent of de novo protein synthesis and induce their release to the extracellular matrix, is a mechanism that appears to be involved in the fetal rejection process, facilitating priming of the maternal organism against the fetal allograft.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032402     DOI: 10.1089/10799900050151094

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  7 in total

Review 1.  Interplay between T helper type 1 and type 2 cytokines and soluble major histocompatibility complex molecules: a paradigm in pregnancy.

Authors:  Irene Athanassakis; S Vassiliadis
Journal:  Immunology       Date:  2002-11       Impact factor: 7.397

2.  Soluble MHC-II proteins promote suppressive activity in CD4+ T cells.

Authors:  Katerina Bakela; Nikos Kountourakis; Michalis Aivaliotis; Irene Athanassakis
Journal:  Immunology       Date:  2015-01       Impact factor: 7.397

Review 3.  Soluble major histocompatibility complex molecules in immune regulation: highlighting class II antigens.

Authors:  Katerina Bakela; Irene Athanassakis
Journal:  Immunology       Date:  2017-12-11       Impact factor: 7.397

4.  Up regulation of the maternal immune response in the placenta of cattle naturally infected with Neospora caninum.

Authors:  Anne Rosbottom; Helen Gibney; Peter Kaiser; Catherine Hartley; Robert F Smith; Rebecca Robinson; Anja Kipar; Diana J L Williams
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

5.  The possible anti-inflammatory role of circulating human leukocyte antigen levels in women with endometriosis after treatment with danazol and leuprorelin acetate depot.

Authors:  I M Matalliotakis; I Athanassakis; A G Goumenou; M A Neonaki; E E Koumantakis; S Vassiliadis; E E Koumantakis
Journal:  Mediators Inflamm       Date:  2001-04       Impact factor: 4.711

6.  Detection in chick embryo of fetoproteins not recognized by the dam's immune system and of soluble alloantigens. Presumptive teratogenic and abortogenic capacity of their specific IgY.

Authors:  Antonio Rodríguez-Burgos
Journal:  BMC Immunol       Date:  2003-06-27       Impact factor: 3.615

Review 7.  The Potential of Soluble Human Leukocyte Antigen Molecules for Early Cancer Detection and Therapeutic Vaccine Design.

Authors:  Amy L Kessler; Marco J Bruno; Sonja I Buschow
Journal:  Vaccines (Basel)       Date:  2020-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.